articleBreast Cancer Research and TreatmentJan 10, 2008Closed access

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

DCDavid CameronMCMichelle CaseyMFMichael F. PressDLDeborah LindquistTPTadeusz Pieńkowski

University of Leeds · GlaxoSmithKline (United States) · +16 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

803
total citations
FWCI
41.66
Percentile
100%
References
20
Citations per year

Authors

24

Topics & keywords

Topics
Keywords
  • Lapatinib
  • Capecitabine
  • Trastuzumab
  • Medicine
  • Internal medicine
  • Oncology
  • Taxane
  • Breast cancer
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding